Premium

2017 ranking of the global top 10 biotech and pharmaceutical companies based on net income (in billion U.S. dollars)

Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license
Loading statistic...
Profits in billion U.S. dollars
--
--
--
--
--
--
--
--
--
--

© Statista 2017

Download Settings Share
Chart type
Datalabels
Share on Social Media
Description Source More information
This statistic shows the 2017 ranking of the top 10 biotech and pharmaceutical companies worldwide, based on net income. The values were taken from the Financial Times 2017 equity screener database. U.S. company Johnson & Johnson was ranked first with a net income of 16.3 billion U.S. dollars.
Biotech and pharmaceutical companies

Pfizer and Johnson & Johnson, both based in the United States, are among the world’s largest biotechnology and pharmaceutical companies based on their net incomes of approximately 16.3 billion U.S. dollars and 8.4 billion U.S. dollars, respectively, as of 2017. Pfizer generated 49.2 billion U.S. dollars of revenue in this year. Johnson & Johnson accumulated a market capitalization of 356 billion U.S. dollars as of 2017. Roche, a Switzerland-based company, is considered one of the leaders in biotech drugs, generating over 32 billion U.S. dollars in 2016 and is expected to reach nearly 39 billion U.S. dollars in biotech prescription drug revenue in 2022.
Lyrica is one of Pfizer’s most successful products. It is an anticonvulsant for neuropathic pain and is also used as therapy for partial seizures. In the EU and in Russia, Lyrica has also been approved to treat general anxiety disorder. In 2016, this prescription medication generated some five billion U.S. dollars in revenue. The United States and France boast the largest number of biotechnology companies in the world by a significant margin. As of 2013, there were 1,165 dedicated biotechnology companies in the United States and 1,284 companies in France.
Show more
Release date
September 2017
Region
Worldwide
Survey time period
as of September 2017
Supplementary notes
Release date represents date figures were accessed. The source gives no information if data is based on financial or calendar years nor about used exchange rates.

Statista Accounts: Access All Statistics. Starting from $588 / Year

Statistics on "Global pharmaceutical industry"

  • Overview
The most important statistics
  • Companies and products
The most important statistics
  • Top companies by revenue
  • R&D, patents, new entities
  • Outlook
The most important statistics

Related Studies: Available to Download in PDF or PPTX Format

Pfizer

All Information
in one Presentation

Pfizer

Everything On "Pfizer" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Other Reports & Dossiers

Statista for Your Company: The Research and Analysis Tool

  • Product Film
  • Statistics
  • Downloads

Our Premium Statistics - facts for your business

Currently, Statista provides more than 1 million statistics.
93 percent (all Premium content) are exclusively accessible via our professional accounts.

Unlimited access

As a Statista Premium customer, you receive unlimited access to all statistics at all times. Including downloads of data in the most common formats (XLS, PDF & PNG). Create relevant and significant statistics in no time.

You are in good company

Further Content: Statistics, Studies, and Topic Pages

Our Business Solutions: Save Time and Money

only

$588*

per year
Your advantages
  • Full access to all our statistics
  • Download as XLS, PDF & PNG
  • Relevant data: complete source information
All functions of our platform illustrated face-to-face
  • Learn how Statista supports your company
  • Extensive tour across the whole portal
  • Personal guidance by our support team
The knowledge database for your company
  • All functions of the Premium Account
  • Access to dossiers, forecasts and studies
  • Access to our international database
  • Publishing rights and other exclusive functions